Keyphrases
Acneiform Rash
15%
Adverse Effects
15%
Adverse Events
17%
ASCO Guidelines
15%
Assessment Score
9%
BRAF Inhibitor (BRAFi)
9%
Cancer Therapy
11%
Cancer Treatment
12%
Clinical Dermatology
15%
Confidence Interval
12%
Corticosteroids
10%
Cytotoxic Agents
15%
Dermatologic Toxicity
23%
Dermatological Adverse Effects
54%
Dermatological Diseases
19%
Dermatologist
22%
Effisayil 1
9%
EGFR Inhibitors
15%
Epidermal Growth Factor Receptor Inhibitors
42%
Erythema
11%
Fever
10%
Generalized Pustular Psoriasis
46%
Graft-versus-host Disease (GvHD)
14%
Hidradenitis Suppurativa
23%
Immune-related Adverse Events
15%
Inhibitor Therapy
16%
Moderate to Severe
12%
Multikinase Inhibitor
13%
National Health Interview Survey
15%
NHANES
15%
Oncologists
12%
Papulopustular Eruption
10%
Paronychia
9%
Patients with Cancer
14%
Physician Global Assessment
11%
Psoriasis
15%
Psoriasis Flare
20%
Randomized Placebo-controlled Trial
15%
Rash
13%
Retrospective Cohort Study
16%
Skin Reactions
14%
Skin Toxicity
12%
Solid Organ Transplant Recipients
9%
Spesolimab
41%
Stevens-Johnson Syndrome
15%
Targeted Therapy
12%
Toxic Epidermal Necrolysis
15%
Treatment Options
12%
Tumor Treating Fields
15%
United States
15%
Medicine and Dentistry
Acne Vulgaris
7%
Acneiform Eruption
9%
Adverse Effect
8%
Adverse Event
54%
Cancer Therapy
12%
Cancer Treatment
10%
Chemotherapy
14%
Chimeric Antigen Receptor T-Cell
7%
Chimeric Antigen Receptor T-Cell Immunotherapy
7%
Clinical Trial
8%
COVID-19
7%
Cytotoxic Agent
10%
Cytotoxic Chemotherapy
11%
Dermatological Agent
100%
Dermatology
13%
Diagnosis
11%
Diseases
24%
EGFR Inhibitors
15%
Epidermal Growth Factor Receptor
19%
Epidermal Growth Factor Receptor Kinase Inhibitor
36%
Erythema
18%
Exanthem
29%
Folliculitis
10%
Generalized Pustular Psoriasis
23%
Glioblastoma
9%
Hidradenitis Suppurativa
31%
Immune-Related Adverse Events
15%
Immunity
13%
Immunosuppressive Drug
8%
Immunosuppressive Treatment
9%
Malignant Neoplasm
11%
Medical Dermatology
15%
Metastatic Colorectal Cancer
9%
Nail
17%
Onychomadesis
7%
Papulopustular
15%
Paronychia
9%
Placebo
8%
Placebo-Controlled Study
8%
Prevalence
8%
Psoriasis
10%
Quality of Life
12%
Retrospective Cohort Study
8%
Side Effect
11%
Skin Manifestation
11%
Skin Toxicity
11%
Systematic Review
21%
T Cell
8%
Transplantation
17%
Tumor Treating Fields
15%